Hormonal
GLP-1RAs confer cardiovascular protection by reducing the risk of major adverse cardiovascular events (MACE), including death from cardiovascular causes, nonfatal myocardial infarction, and nonfatal stroke, particularly in patients with established cardiovascular disease and obesity.
If you have obesity and existing heart disease, GLP-1 receptor agonists like semaglutide can significantly reduce your risk of heart attack, stroke, and cardiovascular death. This benefit is independent of whether you have diabetes, making these medications a crucial part of cardiovascular risk management for obese patients.
GLP-1RAs have been shown to enhance endothelial cell function through anti-inflammatory and vasodilatory mechanisms... GLP-1RAs reduce mortality associated with cardiovascular disease and confer protective effects by decreasing the incidence of myocardial infarction and nonfatal stroke.
Why this rating
Supported by large-scale randomized controlled trials (e.g., STEP trial with 17,604 patients).
Source
The Clinical Application of GLP-1RAs and GLP-1/GIP Dual Receptor Agonists Based on Pharmacological Mechanisms: A Review
Zhao Liu et al. · Drug Design Development and Therapy · 2025
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →